Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

NAEnrolling by invitationINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2027

Conditions
Multiple SclerosisHealthy
Interventions
PROCEDURE

thoracic duct cannulation

"Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel \& advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN \& OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter \& advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath \& pulled out. Catheter then threaded \& advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling."

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Novartis Institutes for BioMedical Research

OTHER

lead

University of Pennsylvania

OTHER